The successful filing of an Investigational New Drug application (IND) is a pivotal milestone for an emerging pharma company. This webinar is designed to address this crucial topic for the key industry segment.
Citing the FDA website for an Investigational New Drug Application, “Current Federal law requires that a drug be the subject of an approved marketing application before it is transported or distributed across state lines. Because a sponsor will probably want to ship the investigational drug to clinical investigators in many states, it must seek an exemption from that legal requirement. The IND is the means through which the sponsor technically obtains this exemption from the FDA.” This webinar is geared towards smaller pharma companies filing an IND for the first time but even experienced drug developers could benefit from an overview of the requirements and considerations. The goal of the webinar is to educate and enable our listeners in pursuit of this key objective. While this particular talk is geared towards small molecule active pharmaceutical ingredients (API) and drug products, much of it applies to biologic products as well.
The Webinar features three prominent experts in the pharmaceutical development arena and each will highlight a different facet of the IND process.
Jennifer Stanek has over 20 years of experience with key roles in CMC regulatory affairs, formulation development and analytical development. She has expertise in the coordination, preparation and management of global clinical trial applications, new marketing registrations, drug master file applications and their life-cycle management. Ms. Stanek began her career at G.D. Searle, moved into CMC consulting and is currently with Takeda where she serves as Director in Global Regulatory Affairs CMC.
Jennifer will be providing an overview of the US IND format including an explanation of Modules 1-5, CMC (Chemistry, Manufacturing & Controls) submission timings, FDA meetings (timing, preparation, etc), and other CMC considerations.
Dan Weissmueller is the Director of Quality at Regis Technologies. Dan’s experience and expertise include analytical development, process and analytical validation, IND support to Regis’ custom API customers, Drug Master File (DMF) regulatory approvals worldwide and FDA inspections. Dan has been with Regis for about 15 years where he has worked with numerous early phase API developments candidates and been the responsible person for the fillings of 3 approved drugs in over 20 countries. Dan is in the process of completing his Masters’ in Quality and Regulatory Sciences from Northwestern University.
Working from the perspective of a custom manufacturing organization (CMO) quality assurance director, Dan has seen both the good and bad in terms of a customer’s preparation for an IND filing. Dan will be highlighting aspects of drug substance development and cGMP scale up as it applies to the IND requirements for small molecule API’s. Topics include the development lifecycle, validation considerations, equipment qualification and risk management.
Steve Pondell brings over 30 years of experience in manufacturing and serves as Vice President of CMC at ESSA Pharmaceuticals and previously as a Principal at Integrated Biotech Solutions in Houston, Texas. Steve is a CMC expert in the manufacturing, compliance and regulatory aspects of product development from clinical manufacturing, through global regulatory approvals and into commercial production. Steve has served a variety of small to medium sized pharma and biotech companies with projects that include GMP Gap Analysis, Phase 1 product development programs, and cGMP compliance.
Steve will focus his talk on the IND requirements for Drug Product along with the corresponding analytical considerations. Topics include container/closure, dosage form (e.g. oral, injectable, etc), analytical method requirements, specifications, validation requirements and product stability.
Steve Pondell, Vice President of CMC, ESSA Pharmaceuticals
Steve Pondell is the Vice President of CMC at ESSA Pharmaceuticals. With over 30 years in the industry, he is a CMC expert in the manufacturing, compliance, and regulatory aspects of product development from clinical manufacturing through global regulatory approvals and into commercial production.Message Presenter
Jennifer Stanek, Director in Global Regulatory Affairs CMC, Takeda
Jennifer Stanek is the Director in Global Regulatory Affairs CMC at Takeda. She has over 20 years experience in key roles within CMC regulatory affairs, formulation development, and analytical development. Stanek began her career at G.D. Searle and has also done CMC consulting.Message Presenter
Dan Weissmueller, Director of Quality, Regis Technologies
Dan Weissmueller is the Director of Quality at Regis Technologies. Over the past 15 years, Weissmueller has developed experience and expertise in analytical development, process and analytical validation, IND support to Regis’ custom API customers, Drug Master File (DMF) regulatory approvals worldwide, and FDA inspections. Dan is in the process of completing his Masters in Quality and Regulatory Sciences from Northwestern University.Message Presenter
Who Should Attend?
Emerging Pharma Participants
- Director / VP Manufacturing
- Director / VP CMC
- Director / VP Quality Assurance
Large Pharma Participants
- Manufacturing, CMC and QA professionals
Regis Technologies, Inc., a Chicago-based CMO focused on small molecule active Pharmaceutical ingredients (API), partners with Pharmaceutical companies to expedite drugs to the clinic and ultimately to the market. We offer synthesis, analytical and separation services to advance your API from initial process development to final validation and commercial manufacturing. Let our veteran project managers successfully guide your molecule through the IND and NDA processes.
Regis Technologies operates an FDA inspected cGMP facility with about 36,000 square feet of production space housing eight reactor suites from 25 to 500 gallons. New for 2015, Regis’ Potent Compound Suite (PCS) is qualified and ready for projects. The PCS addition allows Regis to serve the oncology market by providing for small molecule cGMP manufacturing of potent compounds up to about one kilogram per batch.
Partner with the proven provider since 1956.